Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Objectives
- Idiopathic inflammatory myopathies
- Clinical presentation
- Bohan and Peter criteria
- Advances
- Dermatomyositis and polymyositis
- Idiopathic inflammatory myopathies
- Dermatomyositis
- Dermatomyositis rashes
- Pattern of weakness: dermatomyositis
- Polymyositis
- Inclusion body myositis (IBM)
- Patterns of weakness: IBM
- Asymmetric forearm scooping
- Immune-mediated necrotizing myopathy
- Summary of the different sub-groups
- Evaluation
- Strength testing
- Skin exam
- Assessment for other organ involvement
- Myositis specific antibodies
- Dermatomyositis specific antibodies (1)
- Dermatomyositis specific antibodies (2)
- IMNM specific antibodies
- IBM- related antibody
- Myositis associated antibodies
- Myositis antibodies and clinical associations
- EMG
- MRI
- Muscle biopsy
- Pathology: Dermatomyositis
- Pathology: Polymyositis
- Pathology: IBM
- Pathology: IMNM
- Considerations for treatment
- Treatment options
- Challenges
- Conclusions
Topics Covered
- Clinical presentation of the idiopathic inflammatory myopathies
- Classification criteria for myositis
- Myositis antibodies and clinical associations
- Diagnostic tools and evaluation of myositis
- Treatment strategies for myositis
Links
Categories:
Therapeutic Areas:
Talk Citation
Albayda, J. (2024, July 23). An overview of the idiopathic inflammatory myopathies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/DGQG3830.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jemima Albayda has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
An overview of the idiopathic inflammatory myopathies
A selection of talks on Cardiovascular & Metabolic
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Jemima Albayda.
I'm an Assistant Professor
at the Johns Hopkins University,
seeing patients
at the Division of Rheumatology,
Myositis Center.
Today, I will give you "An overview
of the Idiopathic
Inflammatory Myopathies".
0:17
Our objectives with this talk
are to describe
the clinical presentation
of the idiopathic
inflammatory myopathies.
To define
the subgroups of myositis.
And present the framework
for current understanding
of classification.
To enumerate
the known antibody associations.
And discuss how they help guide
prognosis and management.
To detail the clinical evaluation
of myositis
and the role of ancillary testing.
And to briefly discuss
treatment strategies.
0:47
The idiopathic
inflammatory myopathies
are a rare group of acquired
autoimmune muscle disorders.
Clinically, they are characterized
by muscle weakness
and by inflammatory cell
infiltrates in the muscle.
Although, it is thought
of as a muscle disorder,
it is quite heterogenous
in presentation
and treatment response.
Extramuscular manifestations
are often seen
and can include skin
and lung inflammation,
joint, heart,
and rarely GI tract involvement.
There's also a known increased risk
of malignancy,
particularly,
in cases of dermatomyositis.
1:28
When we think about
how these diseases present,
certain features
are often considered.
There's usually
symmetrical weakness,
usually progressive
of the limb-girdle muscles,
such as the deltoids
and hip flexors.
There's elevation of serum levels
of muscle-associated enzymes,
such as creatine phosphokinase,
aldolase, LDH, and AST, and ALT.
There can be muscle biopsy
evidence of myositis.
And this can include
necrosis of type I
and type II muscle fibers,
phagocytosis, degeneration
and regeneration of myofibers,
and infiltrates,
which are inflammatory
involving the endomysial,
perimysial,
perivascular, interstitial spaces.
There is also often
electrophysiologic
evidence of myopathy.
And these can include short,
small, low-amplitude polyphasic
motor units potentials,
positive fibrillation potentials,
even at rest,
and bizarre high frequency
repetitive discharges.
In the case of dermatomyositis,
characteristic rashes
are often seen.
These features I mentioned
make up the core set
of the most commonly used
and widely accepted
criteria for myositis,